To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Bipolar disorder is an episodic mental illness, often requiring complex pharmacological management. Lithium is a first-line treatment, while antidepressant monotherapy can precipitate mania symptoms in some patients.
Aims
To (a) describe patterns of antidepressant, antipsychotic and mood stabiliser prescribing in the 12-month periods before and after first-recorded bipolar diagnosis; (b) describe treatment trajectories in the year post-diagnosis; and (c) investigate associations between sociodemographic and treatment-related characteristics of (i) antidepressant monotherapy and (ii) lithium prescription post-diagnosis.
Method
A longitudinal cohort study of patients with a first-recorded diagnosis of bipolar disorder between 2000 and 2022 derived from Clinical Practice Research Datalink. Prescriptions for antidepressants, antipsychotics and mood stabilisers were examined in the 12 months before and after diagnosis. Logistic regression models tested associations between sociodemographic and treatment-related characteristics and prescribing outcomes. A web application (https://dop-mhds.shinyapps.io/bpd-prescribing-uk-shiny/) was developed to visualise treatment trajectories over the year following diagnosis.
Results
We included 40 965 patients with a first-recorded diagnosis of bipolar disorder between 2000 and 2022 (median age at diagnosis 43 years, 60.9% female, 11.1% ethnic minority). Of these, 32 460 (79.2%) were prescribed a relevant medication in the year prior to diagnosis compared with 37 208 (90.8%) in the year after. Antidepressant monotherapy was the most common pre-diagnosis treatment (48.4%), but was also prescribed to 28.9% during at least 1 month in the year after diagnosis. Antipsychotic monotherapy was the most common post-diagnosis treatment (36.0%). Lithium was prescribed to 18.5% within 1 year of diagnosis, with 4.0% receiving it as first-line monotherapy. Almost half (46.0%) switched medication at least once within 1 year. Males, ethnic minorities and patients residing in the most deprived areas had lower odds of receiving either lithium or antidepressant monotherapy.
Conclusions
Prescribing patterns for bipolar disorder in the UK are highly variable and often outside of guideline recommendations, with persistent use of antidepressant monotherapy and potential under-utilisation of lithium.
The recent study by Aron et al about lithium deficiency and the onset of Alzheimer’s disease provides a valuable explanatory framework for understanding how very small doses of lithium, delivered via environmental exposure, can exert neuroprotective effects. It also contains results which will need to be reconciled with foundational chemistry and existing evidence and which could be potentially misleading. The suggestion that lithium orotate (LiO) exhibits benefits relative to the more traditionally used lithium carbonate (LiC) requires further scrutiny in light of the following arguments: (a) no study has demonstrated the presence of stable LiO in physiological fluids; (b) acid–base chemistry predicts that LiO will be largely protonated in the stomach, causing it to dissociate and be absorbed as Li+; (c) experimental studies indicate that LiO and LiC have comparable pharmacokinetics after oral administration; and (d) previous research has shown that LiC also has neuroprotective effects, including at very low doses. Disproportionate focus on a specific lithium salt could have safety implications and may distract from answering fundamental questions about the effects of very low doses of lithium. More experiments are needed to provide evidence of a stable LiO complex in physiological fluids before this becomes the main form of lithium in future clinical trials.
Cognitive impairment is a major determinant of disability in bipolar disorder (BD) and a defining feature of both mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Lithium, a first-line maintenance treatment for BD, is implicated in neuroprotective mechanisms including glycogen synthase kinase-3β inhibition, amyloid and tau modulation, and neurogenesis promotion. The overarching aim of this systematic review is to evaluate the long-term effects of lithium on cognition across BD, MCI, and early-to-moderate AD using randomized controlled trial (RCT) evidence. Online databases were searched from inception through May 2025 for RCTs reporting lithium’s effect on cognitive outcomes in BD, MCI, or early-to-moderate AD with ≥8 weeks of follow-up. Risk of bias was assessed using the Cochrane RoB 2 tool. Eight RCTs met the inclusion criteria, ranging from 10 weeks to 3 years in duration. Across four BD trials, lithium did not exhibit consistent improvement or worsening on composite cognitive scores. Three of four MCI/AD trials reported attenuated global cognitive deterioration with low-dose lithium, especially when exposure was ≥12 months. Methodological limitations included small sample sizes, exploratory endpoints, and variable measures for cognitive function as well as lithium strategies. Lithium demonstrates preliminary signals of slower cognitive decline in MCI/AD. Available evidence suggests lithium has neutral effects on cognitive impairment in BD. Future adequately powered RCTs with cognition as a primary endpoint, functional measures, and biomarker outcomes are warranted to clarify lithium’s role as a maintenance treatment in psychiatric disorders and its potential neuroprotective effects in neurodegenerative diseases.
Long-term pharmacological augmentation is central to care for treatment-resistant depression, yet until recently no adequately powered trials have examined it. With three such studies now published, we highlight the hope they offer for improving outcomes in this underserved population while highlighting caution in interpreting their collective findings without careful consideration of methodology and clinical context. We consider these issues and their implications for guiding more personalised treatment decisions aimed at sustained benefit in routine practice.
This chapter explores, for condensed matter formed by other elements, the novel physical and chemical properties that are dominated by full quantum effects. This includes elementary substances including relatively light elements (e.g., helium (He), lithium (Li), carbon (C), and boron (B)) as well as relatively heavy elements (e.g., oxygen (O) and silicon (Si)), and their compounds. The objects studied include liquid and solid helium, lithium bulk metal and clusters, bulk boron, borophene, boron nitride nanotubes, hexagonal boron nitride, magnesium diboride, diamond, graphene, carbon atoms in organic molecules, strontium titanate, barium ferrite, silicon semiconductors, etc. The related physical and chemical properties include superfluidity, supersolidity, elastic or plastic deformation, heat capacity, high-pressure phase diagram, bonding lengths, diffusion, crystal structure, electron–phonon coupling, bandgap renormalization, thermal expansion coefficient, thermal conductivity, phonon frequency distribution, superconducting temperature and light absorption, etc. Through a variety of fruitful aspects readers would overview the situations where full quantum effect is pronounced and even critical.
Lithium is the only true mood stabiliser as it is able to both treat and prevent mania and depression. In practice, its popularity has declined despite discovering it has anti-suicidal and neuroprotective properties. Here, we argue for recognition of its benefits and advocate for its clinical use more widely.
Mannitol (C6H14O6) is a soluble sugar-alcohol that chelates alkali metals and is commonly used to remove adsorbed boron from mineral surfaces before isotopic analysis. Boron (B) and lithium (Li) are both light incompatible elements that substitute in clay minerals; therefore, the potential for mannitol to extract surface adsorbed Li was studied. Lithium was adsorbed on <2 μm kaolinite (KGa-1) and smectite (SWy-1) clays, and on <20 μm quartz, from 1.0 M LiCl and LiOH solutions. Differences in surface attraction for Li+ result from the mineral point of zero charge (PZC) and solution pH. Various concentrations of mannitol (0.1 M, 0.5 M, 1.0 M) were tested for Li-extraction. Efficient Li-extraction requires mannitol concentrations approximating molar amounts of adsorbed Li. Mannitol molecules (>5 nm) cannot enter clay interlayers easily, but nonetheless extracted large amounts of soluble interlayer Li. Smectite adsorbed the most Li (2.2 wt.%) from LiOH, and >99% of it was removed using 0.5 M mannitol at 25°C in 24 h. Lithium bound in the interlayers can then be retrieved for isotopic analysis using NH4Cl cation exchange. This methodological framework for isolating different reservoirs of Li in clay provides a tool for tracking fluid δ7Li evolution during clay alteration. It opens new possibilities for evaluating fluid δ7Li evolution in asteroidal clays. Structural Li records fluid δ7Li at temperatures of neoformation, while interlayer-bound Li preserves the δ7Li of most recent fluids. Overall, this study demonstrates that mannitol is an efficient and environmentally benign alternative to harsh acid extractions for ore-grade Li adsorbed in clays.
This chapter provides multiple-choice questions designed to reinforce and expand your knowledge of bipolar disorder, including symptom presentation and assessment, neurobiology, treatment mechanisms, clinical characteristics of treatments, treatment strategies, and considerations for special populations.
Edited by
Liz McDonald, East London NHS Foundation Trust,Roch Cantwell, Perinatal Mental Health Service and West of Scotland Mother & Baby Unit,Ian Jones, Cardiff University
Making decisions about prescribing medication for mental disorders in childbearing women is a task that may have profound and long-lasting implications for a mother and her family, and it is important that prescribers have access to up-to-date summaries and interpretations of research that examines how safe these medications are in pregnancy and lactation.
Because it is not possible to test a drug’s reproductive safety in randomised controlled trials, research has to rely on less rigorous study designs. The inherent difficulties and other methodological problems have meant that interpretation of the evidence has often been difficult. However, the volume and quality of research has dramatically increased in recent years. Current findings concerning antidepressant, antipsychotic and mood-stabilising medication during pregnancy and lactation are summarised in this chapter, and recommendations for clinical practice are made referring to published guidelines where they are available.
Early economic evaluations (EEE) can evaluate the economic potential of new innovative healthcare solutions. We present a methodological framework for EEE in bipolar disorder and use eLi12 as an illustrative case, a new method to estimate 12-h lithium blood levels when blood sampling deviates from the 12-h timing, enabling more flexibility for patients and better data on 12-h lithium levels.
Methods:
A decision-analytic model evaluated the costs and consequences of eLi12 for the treatment of bipolar disorder from a Danish national healthcare payer perspective, assessing the minimum efficacy threshold where eLi12 would be considered cost-effective compared with standard of care. The primary outcome was net monetary benefit (NMB), and we estimated quality-adjusted life-years (QALYs) assuming a willingness-to-pay threshold of €67,000/QALY gained. Costs associated with bipolar disorder and lithium treatment (e.g. hospitalisations, suicides, lost productivity, implementation costs) were estimated from literature, Danish registries, and expert opinion.
Results:
Assuming 28,000 patients with bipolar disorder whereof 10,000 are treated with lithium, a 2.5% reduction in number of hospitalisations and suicides are sufficient for eLi12 to be considered cost-effective within one year of implementation. When using a longer time horizon, allowing more savings to be included and thus considering a smaller improvement to be sufficient, less than 1% improvement by using eLi12 would be sufficient within a three-year time horizon.
Conclusion:
EEE can evaluate the health economic potential of new innovative methods, supporting early investment decisions and guiding research. eLi12 can have significant healthcare savings, emphasising the relevance of studying clinical implementation.
This chapter examines the development of the “mode of exchange” in Zimbabwe’s diamond sector. Before 2006, Zimbabwe’s small diamond production mostly went to Western Europe. During an extensive boom in diamond production from 2006 to 2010, many diamonds were smuggled out of the country amid foreign sanctions and a decline in the formal sector. Since 2010, the formal sector has bounced back, and many diamonds have been sold to the United Arab Emirates. Since 2016, Western Europe has once again become an export destination. However, in all periods, smuggling around the formal economy has persisted and had significant consequences for state capacity and institutions, which are examined in this chapter. This also traces the mode of exchange for other resources, particularly gold and lithium, which have been increasingly important. However, the drastic increase in diamond production that started in 2006 has uniquely impacted the Zimbabwean state. It provided an outlet to ZANU-PF during the economic collapse and increased political scrutiny, especially after the contested 2008 election, and contributed to the party being able to survive politically.
We hypothesized that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and treatment currently U.S. Food and Drug Administration (FDA) approved to reduce worsening of kidney disease and kidney failure may protect against lithium-induced nephrotoxicity.
Methods
Renal adverse events (AEs) reported to the FDA Adverse Event Reporting System (FAERS) between December 2003 and December 2024 were analyzed using the validated OpenVigil 2.1 platform. Reporting odds ratios (RORs) were computed for the MedDRA terms renal impairment, renal failure, chronic kidney disease (CKD), end-stage renal disease (ESRD), and acute kidney injury (AKI) in association with lithium, semaglutide, and their co-reporting. A disproportionality signal was considered statistically significant when p < 0.05, and the lower bound of the information component (IC025) was greater than 0.
Results
Lithium was associated with significantly elevated reporting odds across all renal AEs, with each outcome exceeding statistical signal thresholds (p < 0.0001, IC025 > 0). In contrast, semaglutide demonstrated inverse associations for renal impairment, renal failure, CKD, and ESRD (RORs = 0.25–0.54), and a neutral association for AKI (ROR = 0.96); however, none met the criteria for a disproportionality signal (IC025 < 0). Co-reported use of lithium and semaglutide did not yield a significant signal for any renal outcome, including AKI (ROR = 5.81, p = 0.015, IC025 < 0).
Conclusions
This observation, provides impetus to conduct adequate, thorough, mechanistic, clinical, and observational studies to determine whether semaglutide (and/or other incretin receptor agonists) could possibly mitigate the risk for, and/or modify the trajectory of, lithium-induced nephrotoxicity.
We consider that the current National Institute for Health and Care Excellence (NICE) guideline CG185 on bipolar disorder does not provide sufficiently specific guidance for the safe monitoring of plasma lithium levels in older people. We feel this needs correction, and laboratories across the UK should lower the range recommended for monitoring older people’s lithium levels in line with guidelines from the International Society for Bipolar Disorder. This would provide a safety net in older people in order to prevent lithium toxicity without compromising efficacy.
This chapter describes material and immaterial labour in the context of the industrial production, resource extraction, and global circulation of the silvery-alkali metal known as lithium. It focuses on the different kinds of material labour involved in lithium’s extraction from local sites in and around the Atacama Desert in Latin America, as well as less visible forms of labour underpinning the mining industry, including the labour of social reproduction and colonial dispossession. In this context, it asks: how do narrative arts document the violence of lithium’s extraction as it materialises in damaged and dispossessed bodies and environments, as well as those less visible traces of lithium’s circulation around the world, and the different affective economies it inhabits? I suggest that a contradiction or tension between materiality and immateriality, between what is seen and unseen, defines every level of lithium’s transformation into a commodity, as registered within global networks of labour. These larger systems, I argue, are rendered invisible; just as lithium silently provides the charge for iPhone and Tesla, it is a vanishing mediator to what some thinkers have described as ‘new extractive imperialism’. This, however, becomes visible—precisely as a kind of ideological dissimulation—across a whole range of narrative forms.
The global energy transition carries significant geopolitical implications. This study examines how Chinese exports of critical electrical goods and geopolitical risk influence national energy transitions, focusing on lithium and rare earth production, pricing and oil markets. Using a Global Vector Autoregressive model across 12 major economies (2012–2019), with emphasis on Australia, China and the United States, the analysis shows that Chinese geopolitical risk affects the consumption of electrical goods, renewable energy deployment and critical mineral production. Empirical findings reveal that reliance on Chinese electrical goods creates strategic dependencies, making other countries vulnerable to shifts in China’s energy strategy. While oil prices are less relevant for most economies’ transitions, they remain central to the United States. The results highlight both the geopolitical risks and cooperative potential embedded in the global shift to clean energy.
Lithium treatment is associated with reduced mortality in bipolar disorder (BD), but the role of treatment continuity remains underexplored. This study investigated the association between patterns of lithium exposure and all-cause mortality in a population-based cohort.
Methods
We analyzed electronic health records from 15,384 individuals with BD in Catalonia, Spain (2010–2019). Patients were classified as having sustained, partial/intermittent, or no lithium exposure based on annual defined daily doses (DDDs). All-cause mortality was the primary outcome. Kaplan–Meier and Cox regression analyses (adjusted for sociodemographic, clinical, and treatment-related variables) estimated hazard ratios (HRs) for mortality risk. Interaction and sensitivity analyses were conducted to assess the role of comorbidity burden and dose effects.
Results
Over the study period, 715 deaths were recorded. In fully adjusted models, sustained lithium exposure was associated with a significantly lower mortality risk compared to no exposure (HR = 0.69, 95% confidence interval [CI]: 0.51–0.93, p = 0.016). In the lithium-exposed subgroup, sustained use was also protective compared to partial/intermittent exposure (HR = 0.70, 95% CI: 0.51–0.97, p = 0.03). No significant interaction was observed between sustained lithium use and comorbidity burden. Sensitivity analyses confirmed this effect at lower dose thresholds but not at higher ones.
Conclusions
Sustained lithium use is associated with improved survival in BD. Discontinuous exposure does not confer the same benefit. Ensuring treatment continuity may maximize lithium’s protective effect and improve long-term outcomes.
Since the 1980s, state capacity has been a major explanation for countries leaving the middle-income trap. However, this literature is unable to explain the failed experiences of countries with relatively high state capacity. This was the case of Chile after the unsuccessful enaction of a series of policies in the mid-2010s to upgrade the country’s position in the lithium value chain. To understand this failure, we combine the literature on developmental states and the literature on business power. We use the concept of institutional business power to understand how business actions erode state capacities leading to countries’ persistent inability to leave the middle-income trap. In the case of Chile, despite the relatively high levels of state capacity, previous processes of deregulation and privatization in the country configured a situation favorable to business’ monopolization of information and technical knowledge about lithium production and innovation processes that directly affected the capacity of the state to regulate the sector, let alone implement policies designed to upgrade the industry. The article highlights the need to investigate further the role of not just the state, but of the private sector in either facilitating or blocking value chain upgrading in countries caught in the middle-income trap.
The scramble to extract critical energy transition minerals creates risk of widespread negative human rights impacts. A just transition in the extraction of critical minerals must involve deep examination of the mine-community interface to gain a better understanding of the drivers of successful engagement between mining companies and communities. Drawing on fieldwork in South America’s lithium triangle, this paper finds that the nature of the corporate-community relationship is increasingly key to enabling a just transition whereby communities participate in the benefits of extraction with negative impacts mitigated. It establishes that key success factors are related to empowerment of Indigenous communities and have the potential to maximise positive outcomes for communities in the context of lithium extraction. Governments and companies must embed a more bottom-up process with an end goal of communities themselves defining the parameters of what a just transition means in the critical minerals context.